Legend Biotech Corporation
NasdaqGS-LEGN
Company Overview
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Name
Legend Biotech Corporation
CEO
Dr. Ying Huang Ph.D.
Website
www.legendbiotech.com
Sector
Biotechnology
Year Founded
2014
Profile
Market Cap
$9,372.84M
EV
$8,419.93M
Shares Out
183.17M
Revenue
$455.99M
Employees
2,200
Margins
Gross
-30.76%
EBITDA
-79.48%
Operating
-81.89%
Pre-Tax
-62.95%
Net
-62.5%
FCF
-35.53%
Returns (5Yr Avg)
ROA
-42.93%
ROTA
-207.46%
ROE
-192.42%
ROCE
-48.99%
ROIC
-110.42%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$82.93
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$1,291.84M
Net Debt
-$952.91M
Debt/Equity
0.29
EBIT/Interest
-16.63
Growth (CAGR)
Rev 3Yr
72.46%
Rev 5Yr
41.94%
Rev 10Yr
—
Dil EPS 3Yr
-10.9%
Dil EPS 5Yr
154%
Dil EPS 10Yr
—
Rev Fwd 2Yr
88.28%
EBITDA Fwd 2Yr
—
EPS Fwd 2Yr
—
EPS LT Growth Est
—
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—